Friday's Top Biotech & Medical Stocks

by H.S. Ayoub
BioHealth Investor.com

Biotechnology

DYAX CORP [DYAX] +49.25%
NANOGEN INC [NGEN] +12.43%
ALFACELL CORP [ACEL] +10.67%
HEMISPHERX BIOPHARMA [HEB] +9.43%
NASTECH PHARM CO [NSTK] +9.37%

Diagnostic Substances

AVALON PHARMACEUTIC [AVRX] +12.77%
CYTOGEN CORP [CYTO] +10.36%
LEXICON GENETICS I [LEXG] +10.19%
GENE LOGIC INC [GLGC] +9.65%
EPIX PHARMACEUTICALS [EPIX] +6.47%

Drug Delivery

DELCATH SYSTEMS INC [DCTH] +7.82%
PENWEST PHARM CO [PPCO] +6.44%
EMISPHERE TECH [EMIS] +5.93%
MATRIXX INITIATVS [MTXX] +5.86%
BIOPROGRESS PLC [BPRG] +3.41%

Drug Manufacturers

LANNETT COMPANY INC [LCI] +11.22%
NITROMED, INC. [NTMD] +9.55%
ADVANCIS PHARMA CP [AVNC] +8.51%
MERCK CO INC [MRK] +8.30%
OSCIENT PHARMACEUT [OSCI] +7.90%

Drug Related Products

PRESTIGE BRAND HLGS [PBH] +5.44%
MEDICAL NUTRITN USA [MDNU.OB] +2.20%
N B T Y INC [NTY] +1.91%
MANNATECH INC [MTEX] +1.66%
DRAXIS HEALTH INC [DRAX] +1.57%

Generic Drugs

ISOLAGEN INC [ILE] +9.09%
HI-TECH PHARMACAL [HITK] +2.74%
BARR PHARMA INC [BRL] +2.04%
MYLAN LABS INC [MYL] +0.60%
CARACO PHARMA LABS [CPD] +0.07%

Medical Appliances & Equipment

SPECTRASCIENCE NEW [SCIE.OB] +13.56%
ALPHA INNOTECH [APNO.OB] +11.11%
MEDIS TECH LTD [MDTL] +11.10%
MICROTEK MED HLDGS [MTMD] +8.79%
CANDELA CP [CLZR] +8.54%

Medical Instruments & Supplies

OPHTHALMIC IMAGING SYS INC [OISI.OB] +9.80%
EP MEDSYSTEMS INC [EPMD] +9.68%
ENPATH MED INC [NPTH] +9.66%
NEUROMETRIX, INC. [NURO] +9.01%
MEMRY CORPORATION [MRY] +8.67%

Medical Laboratories & Research

MEDASORB TECHNOLOGS [MSBT.OB] +16.67%
MEDTOX SCIENTFIC INC [MTOX] +9.62%
BIO-IMAGING TECH [BITI] +7.63%
SPHERIX INC [SPEX] +5.60%
NEOGENOMICS INC [NGNM.OB] +3.23%

- Thursday's Top Biotech and Medical Stocks
- Wednesday's Top Biotech and Medical Stocks

____________________

4 Comments:

Anonymous said...: Nastech stock is the most manipulated stock by hedge funds,
mutual funds and shorts. It is now
joined by the pirates from the cramer group and dndn group who
are masters of manipulation.
POOR MANAGEMENT,POOR FUNDAMENTALS,POOR RATINGS,POOR FDA EXPERIENCES,
POOR PARTNERSHIP EXPERIENCES AND HORRIFIC EARNINGS PER SHARE. FIVE PRESTIGIOUS INVESTMENT WEB SITES, NUMEROUS PERIODICALS RATE A SELL OR AVOID AND CALL IT WHAT IT IS. THEIR REPUTATIONS AND CREDITABILITY SUPERSEDE ALL THE CURRENT HYPE PERIOD!
IN ACTUALITY THE CURRENT RUN UP WILL BE FOLLOWED BY SHORTING AS USUAL, BECAUSE THE DISMAL EARNINGS REPORT IS DUE SOON. THIS ISN'T AN INTELLECTUAL INVESTMENT BY INVESTORS, RATHER INVESTORS WHO ARE DEGENERATE GAMBLERS
BY PROFESSION.
TIP:SINCE LONGS THINK CEO, QUAY CAN DO NO WRONG, THEY SHOULD PLAY THE KENTUCKY DERBY AND BET ON
"CIRCULAR QUAY"
THIS MAKES ABOUT AS MUCH SENSE AS INVESTING IN NASTECH!
MR.REALITY; 9:34 AM
Anonymous said...: I applaud the most recent comment posted about Nastech!
The poster dissected nstk properly
and the investors will soon find themselves in a quadmeyer after the soon to be published earnings report. The foundation of nstk is unstable and there are many
severe cracks and violations that investors are not willing to address due to the current Hype.
When nstk(building) collapses
the majority of shareholders will be the victims of the ensuing disaster to come.; 11:18 AM
Anonymous said...: August 2, 2007
It is a shame that companies are not held responsible and accountable for what is posted on the their Profile under 'business summary'. Case in point Nastech Pharmaceutical. Some say it's yahoo's fault not NSTK but I say it's the fiduciary duty of Investor relations to have something removed from it's business summary that is unwarranted to mislead new investors. They still have as one of their partners MERCK, however Merck dropped NSTK over a year ago. When a press release is given it also states it as well.
You say what's the Big Deal but it's not true any longer! As far as having a T.V. celebrity TOUT nstk 17 times since March 16th to date is a mystery of sorts. Why, and people buy it because he touts it.
There is a reason for everything but his motive is unclear at this point!
The company is over financed, the stock should test new lows soon, and their competitors have had success in the past with the FDA and their stats are lessons for nstk's management to observe and duplicate if they really want to turn the comapny around. They are light years away from approvals so why buy it now like Cramer keeps touting this stock to death?
Biohealth Investor has solid information for investors to go by than what I call T.V.TOUTS!; 8:51 AM
Anonymous said...: MANY RNAI STUDIES, REPORTS, AND ARTICLES ARE COMING OUT ALMOST EVERY OTHER WEEK AS 2007 HEADS INTO THE FINAL QUARTER. IT IS EVIDENT THAT MUCH HAS TO BE DONE, AND PROVEN IN THE NEXT DECADE AS SO MANY SCIENTISTS HAVE BEEN REPORTING.WHICH LEADS ME TO THE COMMENTS MADE ON JULY 26TH BY JIM CRAMER. HE SAID "I URGE YOU TO BUY 'NSTK' ON HIS VIDEO BECAUSE OF RNAI.
WHAT'S PUZZLING IS THE FACT THAT RNAI ACCORDING TO PUBLISHED REPORTS, ARE QUITE SOME YEARS AWAY FROM PERFECTING THE STUDY AND SAFETY BEFORE APPLICATION. HAVING SAID THIS, WHY WOULD CRAMER TELL INVESTORS TO BUY 'NSTK' NOW, WHEN TRADITIONALLY THE STOCK SUFFERS IN DECEMBER, JANUARY, AND FEBRUARY DUE TO YEAR END EARNINGS REPORTS THAT COME OUT IN MARCH 2008. WOULDN'T IT MAKE SENSE TO BUY THE STOCK IF IT'S 20-40% CHEAPER IN MARCH 2008?; 8:35 AM